Clinical Trials Logo

brca1 Mutation Carrier clinical trials

View clinical trials related to brca1 Mutation Carrier.

Filter by:

NCT ID: NCT00899145 Withdrawn - Breast Carcinoma Clinical Trials

Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

Start date: May 2008
Phase: N/A
Study type: Observational

This research study is looking at breast cancer risk in women who are BRCA1/BRCA2 mutation carriers. Studying samples of DNA in the laboratory from women who are BRCA1/BRCA2 mutation carriers may help doctors identify biomarkers related to cancer.

NCT ID: NCT00897455 Recruiting - Breast Cancer Clinical Trials

Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

Start date: April 2008
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of DNA in the laboratory from women who are BRCA1/BRCA2 mutation carriers may help doctors learn more about cancer and identify biomarkers related to cancer. PURPOSE: This research study is looking at breast cancer risk in women who are BRCA1/BRCA2 mutation carriers.

NCT ID: NCT00892736 Completed - Breast Carcinoma Clinical Trials

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Start date: April 20, 2009
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of veliparib in treating patients with malignant solid tumors that do not respond to previous therapy. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00673335 Completed - Breast Cancer Clinical Trials

Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation

LIBER
Start date: May 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: Letrozole may prevent breast cancer in postmenopausal women with a BRCA1 or BRCA2 mutation. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in preventing breast cancer in postmenopausal women with a BRCA1 or BRCA2 mutation.

NCT ID: NCT00664781 Completed - Breast Cancer Clinical Trials

Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer

Start date: December 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and best dose of rucaparib and to see how well it works in treating patients with locally advanced or metastatic breast cancer or advanced ovarian cancer.

NCT ID: NCT00535119 Completed - Clinical trials for Adult Solid Neoplasm

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Start date: September 2007
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of veliparib when given together with carboplatin and paclitaxel in treating patients with advanced solid cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving veliparib together with carboplatin and paclitaxel may help kill more tumor cells.

NCT ID: NCT00321633 Completed - Breast Cancer Clinical Trials

Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer

Start date: September 2005
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether carboplatin is more effective than docetaxel in treating patients with metastatic genetic breast cancer. PURPOSE: This randomized phase II trial is studying carboplatin to see how well it works compared to docetaxel in treating women with metastatic genetic breast cancer.

NCT ID: NCT00098800 Completed - Ovarian Cancer Clinical Trials

Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries

Start date: October 2004
Phase: N/A
Study type: Interventional

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of fenretinide may prevent ovarian cancer. PURPOSE: This randomized clinical trial is studying how well fenretinide works in preventing ovarian cancer in participants who are at high risk of developing ovarian cancer and planning to undergo surgery to remove the ovaries.

NCT ID: NCT00084370 Withdrawn - Ovarian Cancer Clinical Trials

Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy

Start date: June 2002
Phase: N/A
Study type: Interventional

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib before prophylactic oophorectomy may be an effective way to prevent the development of ovarian epithelial cancer. PURPOSE: A controlled pilot trial to study the effectiveness of celecoxib in preventing cancer in patients at high-risk for ovarian epithelial cancer who are undergoing prophylactic oophorectomy.

NCT ID: NCT00080756 Active, not recruiting - Breast Cancer Clinical Trials

Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease

Start date: March 11, 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Deslorelin combined with low-dose add-back estradiol and testosterone (given to replace hormones suppressed by deslorelin) may be effective in preventing breast cancer in at-risk women. PURPOSE: This phase II trial is studying how well giving deslorelin together with estradiol and testosterone works in preventing breast cancer in premenopausal women who are at high risk for this disease.